Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-05

NCT02815280 is registered in ClinicalTrials.gov with Vyne Therapeutics Inc. as lead sponsor.

NCT NCT02815280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02815280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-05
Lead sponsor
Vyne Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2016
Completion date
October 13, 2017
Enrollment
495 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris